Virginai Mason regimen for pancreatic cancer – pro
The VIrginai Mason approach combined cisplatin, interfeon alpha and 5FU in either an unresectable, neoadjuvant or adjuvant settings. It was somewhat popular in the early 2000s, but then fell out of favor and it si not recommended by NCCN or other guidelines. Interestingly, Yoh presented results of long term survivors in his institution, and many of them received this regimen; however, as already noted, there are no large randomized prospective studies supporting it.
Pisters PW, Evans DB.Cisplatin, fluorouracil, interferon-alpha, and radiation as adjuvant therapy for resected pancreatic cancer: is there a future for this regimen and/or should we change our approach to research and treatment of patients with pancreatic cancer?Ann Surg. 2008 Aug;248(2):152-3.
Stephen Y oh, Alicia Edwards, Margaret T Mandelson, Bruce Lin, Russell Dorer, W Scott Helton, Richard A Kozarek, and Vincent J Picozz, iRare long-term survivors of pancreatic adenocarcinoma without curative resection. World J Gastroenterol. 2015 Dec 28; 21(48): 1357413581.
NCCN, Pancreatic PANC-G, 1.